Table 1

Demographic, clinical, and laboratory information of patients

Subject

Sex

Age (years)

Medications

CRP (mg/l)

ESR (mm/hour)

RA Patients

RA-1a^a

Male

65

None

4.14^b

9

RA-1b

Male

65

MTX

11.8

18

RA-2

Female

33

Etanercept, naproxen

25.7

18

RA-3

Female

43

Etanercept

No data

No data

RA-4

Female

45

None

98.4

84

RA-5

Female

55

MTX

4.8

26

RA-6

Female

73

None

2.1

30

RA-7

Female

51

Hydroxychloroquine, MTX, prednisone

No data

15

RA-8

Male

61

Prednisone, MTX, hydroxychloroquine, sulfasalazine

No data

1

RA-9

Male

46

Methylprednisolone, MTX, etanercept

2

9

RA-10

Female

32

Leflunomide

94.2

63

RA-11

Female

50

Etanercept, MTX

No data

No data

RA-12

Male

67

MTX, celecoxib, prednisone

0.6

11

RA-13

Female

55

MTX

No data

17

RA-14

Female

33

Hydroxychloroquine, ibuprofen

2.8

7

RA-15

Female

55

None

168.2

88

RA-16

Female

56

Prednisone, minocycline

No data

No data

Disease control individuals

SLE1

Female

36

Hydroxychloroquine, prednisone, mycophenolate mofetil

SjS1

Female

30

Hydroxychloroquine, mycophenolate mofetil

SjS2

Male

21

Hydroxychloroquine

SSc1

Female

57

Cyclosporine, hydroxychloroquine, prednisone, mycophenolate mofetil

^aSample collected from RA-1 before and after MTX treatment. ^bNormal value less than 0.8. The normal CRP is <4.9 mg/l, and the normal ESR is <20 mm/hour for females and <10 mm/hour for males. CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; MTX, methotrexate; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SjS, Sjögren's syndrome; SSc, scleroderma.

Pauley et al. Arthritis Research & Therapy 2008 10:R101   doi:10.1186/ar2493